相关实验视频

Updated: Sep 18, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

PD-1/PD-L1 抑制剂 (A56,HD10) 的比较药效:PD-L1 暴露和疗效的跨物种差异

Annoor Awadasseid¹, Rui Wang², Koutian Zhang³

¹Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing 313299, China; Zhejiang Qingzhenghong Technology Co, Ltd, Hangzhou 311121, China.

Bioorganic & medicinal chemistry

|June 22, 2025

概括

针对PD-1/PD-L1通路的小分子抑制剂在癌症免疫治疗中表现有前途. 这项研究证明了它们在人体和小鼠模型中的有效性,强调了对免疫检查点抑制剂的特定物种评估的需要.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

PD-1/PD-L1免疫检查点对于瘤免疫逃避至关重要,也是癌症免疫治疗的关键目标.
小分子抑制剂为单克隆抗体提供了替代品,但PD-L1表达的跨物种差异带来了临床前挑战.

研究的目的:

调查小分子抑制剂A56和HD10针对PD-1/PD-L1.1的跨物种药用性.
在人类和小鼠模型中比较它们的结合亲和力,免疫调节和抗瘤功效.
评估小鼠PD-1和人类PD-L1作为免疫检查点的体内功能.

主要方法:

在人类和小鼠PD-L1模型中对小分子抑制剂A56和HD10进行比较分析.
评估结合亲和力,通过流动细胞计量进行免疫调节,以及抗瘤疗效.
在体内研究以评估T细胞透和抗瘤活性.

主要成果:

表明小鼠PD-1和人类PD-L1在体内形成功能性免疫检查点.
在人类和小鼠模型中,A56和HD10增强了CD8+T细胞透和抗瘤活性.
在人类和小鼠PD-L1环境之间观察到免疫反应的显著差异.

结论:

强调了为免疫检查点抑制剂开发进行特定物种评估的重要性.
强调需要在临床前研究中仔细选择动物模型.
支持A56和HD10作为具有成本效益的,口服可用的免疫疗法的潜力,用于进一步的临床研究.

关键词:

癌症免疫疗法癌症免疫疗法这是一种PD-1/PD-L1抑制剂.小分子是小分子.特定物种的免疫反应.同源和人性化的模型.

更多相关视频

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

相关概念视频

Dose-Response Relationship: Potency and Efficacy

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...